A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Elit, Laurie
  • Konner, JA
  • Armstrong, DK
  • Buck, M
  • Dean, A
  • Finkler, NJ
  • Hulstine, A
  • Schweizer, C
  • Phillips, M
  • Weil, S

publication date

  • May 20, 2010